Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 36.64% is 149% above its 5-year average of -74.80%, near the high end of its 5-year range (-505.54%–36.64%).
As of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 36.64%.
RETURN ON EQUITY (ROE)
36.64%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
-140.11%
RETURN ON EQUITY (ROE) AVG 5Y
-74.80%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+126.15%
CURRENT VS 5Y AVG
+148.98%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+187.21%
vs the sector median at left
MeiraGTx Holdings plc
Market Cap
$981.66M
Return on Equity (ROE)
36.64%
TTM Avg
N/A
3Y Avg
-140.11%
5Y Avg
-74.80%
Market Cap
$982.46M
Return on Equity (ROE)
-25.78%
TTM Avg
29.18%
3Y Avg
31.59%
5Y Avg
31.59%
Market Cap
$978.09M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.93M
Return on Equity (ROE)
2.18%
TTM Avg
-5.89%
3Y Avg
-1.23%
5Y Avg
4.05%
Market Cap
$992.14M
Return on Equity (ROE)
N/A
TTM Avg
151.31%
3Y Avg
46.92%
5Y Avg
11.01%
Market Cap
$996.65M
Return on Equity (ROE)
-32.27%
TTM Avg
-24.43%
3Y Avg
-32.70%
5Y Avg
-40.03%
Market Cap
$998.69M
Return on Equity (ROE)
-63.62%
TTM Avg
-41.08%
3Y Avg
-23.78%
5Y Avg
-22.76%
Market Cap
$1.01B
Return on Equity (ROE)
-52.47%
TTM Avg
-18.98%
3Y Avg
-16.96%
5Y Avg
-116.25%
Market Cap
$953.81M
Return on Equity (ROE)
-15.09%
TTM Avg
46.85%
3Y Avg
62.20%
5Y Avg
62.20%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | $981.66M | 36.64% | N/A | -140.11% | -74.80% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | -25.78% | 29.18% | 31.59% | 31.59% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 2.18% | -5.89% | -1.23% | 4.05% |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | N/A | 151.31% | 46.92% | 11.01% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | -32.27% | -24.43% | -32.70% | -40.03% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | -63.62% | -41.08% | -23.78% | -22.76% |
| Immatics N.V. (IMTX)vs › | $1.01B | -52.47% | -18.98% | -16.96% | -116.25% |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | -15.09% | 46.85% | 62.20% | 62.20% |
| Savara Inc. (SVRA)vs › | $952.91M | -96.97% | -57.21% | -47.20% | -49.27% |
ROE
36.6%
ROA
19.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 36.64% |
| 2025-03-31 | -505.54% |
| 2024-12-31 | -217.89% |
| 2024-09-30 | -92.10% |
| 2024-06-30 | -116.37% |
| 2024-03-31 | -60.87% |
| 2023-12-31 | -60.81% |
| 2023-09-30 | -143.17% |
| 2023-06-30 | -100.82% |
| 2023-03-31 | -142.91% |
| 2022-12-31 | -110.09% |
| 2022-09-30 | -91.48% |
| 2022-06-30 | -71.05% |
| 2022-03-31 | -53.93% |
| 2021-12-31 | -42.91% |
| 2021-09-30 | -42.65% |
| 2021-06-30 | -29.46% |
| 2021-03-31 | -29.86% |
| 2020-12-31 | -24.31% |
| 2020-09-30 | -29.60% |
| 2020-06-30 | -33.02% |
| 2020-03-31 | -28.36% |
| 2019-12-31 | -28.69% |
| 2019-09-30 | -36.08% |
| 2019-06-30 | -58.11% |
| 2019-03-31 | -58.47% |
| 2018-12-31 | -102.23% |
| 2018-09-30 | -73.09% |
| 2018-06-30 | -58.48% |
| 2018-03-31 | -105.67% |
